Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
- Conditions
- COVID-19COVID-19 Immunisation
- Interventions
- Biological: mRNA-1273
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2024-03-18
- Target Recruit Count
- 120
- Registration Number
- NCT04283461
- Locations
- πΊπΈ
Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States
πΊπΈThe Hope Clinic of Emory University, Decatur, Georgia, United States
πΊπΈNational Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program, Bethesda, Maryland, United States
Adaptive COVID-19 Treatment Trial (ACTT)
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2022-03-14
- Target Recruit Count
- 1062
- Registration Number
- NCT04280705
- Locations
- πΊπΈ
University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States
πΊπΈJohns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States
πΊπΈThe University of Washington - Virology Research Clinic, Seattle, Washington, United States
Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals
- Conditions
- HIV InfectionLTBI
- Interventions
- Drug: Dolutegravir (DTG)Drug: Isoniazid (INH)Drug: Rifapentine (RPT)Drug: Antiretroviral Therapy (ART)Dietary Supplement: Pyridoxine (Vitamin B6)
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-08-12
- Target Recruit Count
- 37
- Registration Number
- NCT04272242
- Locations
- πΏπ¦
University of Cape Town Lung Institute (UCTLI) CRS, Cape Town, South Africa
πΊπΈUniversity of California HIV/AIDS CRS, San Francisco, California, United States
πΊπΈHouston AIDS Research Team CRS, Houston, Texas, United States
Phase 2 Shigella Vaccine and Challenge
- Conditions
- Shigella InfectionImmunisation
- Interventions
- Other: PlaceboBiological: Shigella sonnei strain 53GBiological: WRSs2
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-07-26
- Target Recruit Count
- 108
- Registration Number
- NCT04242264
- Locations
- πΊπΈ
The Hope Clinic of Emory University, Decatur, Georgia, United States
πΊπΈCincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati, Ohio, United States
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
- Conditions
- HIV InfectionsNon-Alcoholic Fatty Liver Disease
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 51
- Registration Number
- NCT04216589
- Locations
- πΊπΈ
Ohio State University CRS (Site ID: 2301), Columbus, Ohio, United States
πΊπΈHouston AIDS Research Team CRS (Site ID: 31473), Houston, Texas, United States
πΊπΈUniversity of Washington AIDS CRS (Site ID: 1401), Seattle, Washington, United States
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants
- Conditions
- HIV Infections
- Interventions
- Biological: PGT121.414.LSBiological: VRC07-523LS
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2024-12-13
- Target Recruit Count
- 33
- Registration Number
- NCT04212091
- Locations
- πΊπΈ
George Washington Univ. CRS, Washington, District of Columbia, United States
πΊπΈColumbia P&S CRS, New York, New York, United States
πΊπΈThe Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States
Safety and Pharmacokinetics of VT-1598
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2024-07-26
- Target Recruit Count
- 48
- Registration Number
- NCT04208321
- Locations
- πΊπΈ
ICON Early Phase Services Clinical Research Unit, San Antonio, Texas, United States
Trial to Evaluate CIS43LS in Healthy Adults
- Conditions
- Malaria
- Interventions
- Drug: VRC-MALMAB0100-00-ABOther: Plasmodium falciparum (P. falciparum) sporozoite challenge
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2023-04-18
- Target Recruit Count
- 71
- Registration Number
- NCT04206332
- Locations
- πΊπΈ
University of Maryland Baltimore, Center for Vaccine Development, Baltimore, Maryland, United States
πΊπΈVRC Clinic, NIH Clinical Center, Bethesda, Maryland, United States
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
- Conditions
- HIV InfectionHepatitis B
- Interventions
- Biological: HEPLISAV-BBiological: ENGERIX-B
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2024-11-14
- Target Recruit Count
- 640
- Registration Number
- NCT04193189
- Locations
- πΊπΈ
UCLA CARE Center CRS, Los Angeles, California, United States
πΊπΈRush University CRS, Chicago, Illinois, United States
πΊπΈBrigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS, Boston, Massachusetts, United States
Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults
- Conditions
- HIV Infections
- Interventions
- Biological: BG505 SOSIP.664 gp140Biological: PlaceboBiological: GLA-LSQBiological: CpG 1018Biological: 3M-052-AFBiological: Alum (Aluminum Hydroxide Suspension)Biological: Trimer 4571
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2024-12-04
- Target Recruit Count
- 127
- Registration Number
- NCT04177355
- Locations
- πΊπΈ
Penn Prevention CRS, Philadelphia, Pennsylvania, United States
πΊπΈThe Ponce de Leon Center CRS, Atlanta, Georgia, United States
πΊπΈThe Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States